SUPPLEMENT

Q2 2022 — Financial disclosures

Q2 2022PDF · 10 pages1.0 MB
Merck & Co., Inc.
Financial Highlights Package
Second Quarter 2022
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 2Q22 and June YTD 22.......3
Table 2b: GAAP to Non-GAAP Reconciliation 2Q21 and June YTD 21.......4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / Ex- U.S. 2Q22........................................................6
Table 3b: Sales – U.S. / Ex- U.S. June YTD 22............................................7
Table 3c: Sales – Pharmaceutical Geographic Split....................................8
Table 4: Other (Income) Expense .............................................................9

-- 1 of 10 --

Sales 	14,593	$ 	11,402	$ 	28% 	30,494	$ 	22,029	$ 	38%
Costs, Expenses and Other
Cost of sales 	4,216 	3,104 	36% 	9,596 	6,303 	52%
Selling, general and administrative 	2,512 	2,281 	10% 	4,834 	4,468 	8%
Research and development 	2,798 	4,321 	-35% 	5,374 	6,732 	-20%
Restructuring costs 	142 	82 	73% 	194 	380 	-49%
Other (income) expense, net 	438 	(103) 	* 	1,148 	(558) 	*
Income from Continuing Operations Before Taxes 	4,487 	1,717 	* 	9,348 	4,704 	99%
Income Tax Provision 	538 	503 	1,092 	741
Net Income from Continuing Operations 	3,949 	1,214 	* 	8,256 	3,963 	*
Less: Net Income Attributable to Noncontrolling Interests 	5 	1 	2 	5
Net Income from Continuing Operations Attributable to Merck &
Co., Inc. 3,944 	1,213 	* 	8,254 	3,958 	*
Income from Discontinued Operations, Net of Taxes and Amounts
Attributable to Noncontrolling Interests - 	332 	* 	- 	766 	*
Net Income Attributable to Merck & Co., Inc. 	3,944	$ 	1,545	$ 	* 	8,254	$ 	4,724	$ 	75%
Basic Earnings per Common Share Attributable to Merck & Co., Inc.
Common Shareholders:
Income from Continuing Operations 	1.56	$ 	0.48	$ 	* 	3.26	$ 	1.56	$ 	*
Income from Discontinued Operations 	- 	0.13 	* 	- 	0.30 	*
Net Income 	1.56	$ 	0.61	$ 	* 	3.26	$ 	1.87	$ 	74%
Earnings per Common Share Assuming Dilution Attributable to
Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.55	$ 	0.48	$ 	* 	3.25	$ 	1.56	$ 	*
Income from Discontinued Operations 	- 	0.13 	* 	- 	0.30 	*
Net Income 	1.55	$ 	0.61	$ 	* 	3.25	$ 	1.86	$ 	75%
Average Shares Outstanding 	2,531 	2,533 	2,529 	2,532
Average Shares Outstanding Assuming Dilution 	2,540 	2,540 	2,538 	2,540
Tax Rate from Continuing Operations 	12.0% 	29.3% 	11.7% 	15.8%
* 100% or greater
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
2Q22
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new,
independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the
spin-off are excluded from sales and expenses and reflected as discontinued operations in the company’s Consolidated Statement of Income provided
below.
2Q21 June YTD
2022
June YTD
2021
1

-- 2 of 10 --

Sales 	15,901	$ 	14,593	$ 	30,494	$ 	10,627	$ 	11,402	$ 	22,029	$ 	13,154	$ 	13,521	$ 	48,704	$ 	28% 	38%
Costs, Expenses and Other
Cost of sales 	5,380 	4,216 	9,596 	3,199 	3,104 	6,303 	3,450 	3,873 	13,626 	36% 	52%
Selling, general and administrative 	2,323 	2,512 	4,834 	2,187 	2,281 	4,468 	2,336 	2,830 	9,634 	10% 	8%
Research and development 	2,576 	2,798 	5,374 	2,412 	4,321 	6,732 	2,445 	3,068 	12,245 	-35% 	-20%
Restructuring costs 	53 	142 	194 	297 	82 	380 	107 	174 	661 	73% 	-49%
Other (income) expense, net 	708 	438 	1,148 	(455) 	(103) 	(558) 	(450) 	(333) 	(1,341) 	* 	*
Income from Continuing Operations Before Taxes 	4,861 	4,487 	9,348 	2,987 	1,717 	4,704 	5,266 	3,909 	13,879 	* 	99%
Income Tax Provision 	554 	538 	1,092 	238 	503 	741 	695 	85 	1,521
Net Income from Continuing Operations 	4,307 	3,949 	8,256 	2,749 	1,214 	3,963 	4,571 	3,824 	12,358 	* 	*
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	5 	2 	4 	1 	5 	4 	4 	13
Net Income from Continuing Operations Attributable to Merck &
Co., Inc.
4,310 	3,944 	8,254 	2,745 	1,213 	3,958 	4,567 	3,820 	12,345 	* 	*
Income (Loss) from Discontinued Operations, Net of Taxes and
Amounts Attributable to Noncontrolling Interests
- 	- 	- 	434 	332 	766 	- 	(62) 	704 	* 	*
Net Income Attributable to Merck & Co., Inc. 	4,310	$ 	3,944	$ 	8,254	$ 	3,179	$ 	1,545	$ 	4,724	$ 	4,567	$ 	3,758	$ 	13,049	$ 	* 	75%
Basic Earnings (Loss) per Common Share Attributable to Merck
& Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.56	$ 	3.26	$ 	1.08	$ 	0.48	$ 	1.56	$ 	1.81	$ 	1.51	$ 	4.88	$ 	* 	*
Income (Loss) from Discontinued Operations 	- 	- 	- 	0.17 	0.13 	0.30 	- 	(0.02) 	0.28 	* 	*
Net Income 	1.70	$ 	1.56	$ 	3.26	$ 	1.26	$ 	0.61	$ 	1.87	$ 	1.81	$ 	1.49	$ 	5.16	$ 	* 	74%
Earnings (Loss) per Common Share Assuming Dilution
Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations 	1.70	$ 	1.55	$ 	3.25	$ 	1.08	$ 	0.48	$ 	1.56	$ 	1.80	$ 	1.51	$ 	4.86	$ 	* 	*
Income (Loss) from Discontinued Operations 	- 	- 	- 	0.17 	0.13 	0.30 	- 	(0.02) 	0.28 	* 	*
Net Income 	1.70	$ 	1.55	$ 	3.25	$ 	1.25	$ 	0.61	$ 	1.86	$ 	1.80	$ 	1.48	$ 	5.14	$ 	* 	75%
Average Shares Outstanding 	2,528 	2,531 	2,529 	2,531 	2,533 	2,532 	2,530 	2,527 	2,530
Average Shares Outstanding Assuming Dilution 	2,537 	2,540 	2,538 	2,541 	2,540 	2,540 	2,536 	2,535 	2,538
Tax Rate from Continuing Operations 	11.4% 	12.0% 	11.7% 	8.0% 	29.3% 	15.8% 	13.2% 	2.2% 	11.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
2Q June
YTD
June YTD
2022
2Q 	June YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2021
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
2

-- 3 of 10 --

Second Quarter
Cost of sales 	4,216	$ 	451 	67 	518 	3,698	$
Selling, general and administrative 	2,512 	65 	27 	92 	2,420
Research and development 	2,798 	12 	22 	34 	2,764
Restructuring costs 	142 	142 	142 	-
Other (income) expense, net 	438 	2 	234 	236 	202
Income from Continuing Operations Before Taxes 	4,487 	(530) 	(258) 	(234) 	(1,022) 	5,509
Income Tax Provision (Benefit) 	538 	(131) (3) (40) (3) (52) (3) (223) 	761
Net Income from Continuing Operations 	3,949 	(399) 	(218) 	(182) 	(799) 	4,748
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,944 	(399) 	(218) 	(182) 	(799) 	4,743
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.55	$ 	(0.16) 	(0.09) 	(0.07) 	(0.32) 	1.87	$
Tax Rate 	12.0% 	13.8%
June YTD
Cost of sales 	9,596	$ 	1,131 	113 	1,244 	8,352	$
Selling, general and administrative 	4,834 	115 	48 	163 	4,671
Research and development 	5,374 	34 	29 	63 	5,311
Restructuring costs 	194 	- 	194 	194 	-
Other (income) expense, net 	1,148 	(112) 	918 	806 	342
Income from Continuing Operations Before Taxes 	9,348 	(1,168) 	(384) 	(918) 	(2,470) 	11,818
Income Tax Provision (Benefit) 	1,092 	(286) (3) (62) (3) (204) (3) (552) 	1,644
Net Income from Continuing Operations 	8,256 	(882) 	(322) 	(714) 	(1,918) 	10,174
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 8,254 	(882) 	(322) 	(714) 	(1,918) 	10,172
Earnings per Common Share Assuming Dilution from
Continuing Operations 3.25	$ 	(0.35) 	(0.13) 	(0.28) 	(0.76) 	4.01	$
Tax Rate 	11.7% 	13.9%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for
or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration,
transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible
assets. Amount included in other (income) expense, net, for the six month period primarily reflects royalty income and a decrease in the estimated fair value measurement of liabilities for contingent
consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring
programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal
3

-- 4 of 10 --

Second Quarter
Cost of sales 	3,104	$ 	345 	38 	37 (3) 420 	2,684	$
Selling, general and administrative 	2,281 	25 	2 	27 	2,254
Research and development 	4,321 	16 	6 	22 	4,299
Restructuring costs 	82 	82 	82 	-
Other (income) expense, net 	(103) 	117 	(258) 	(141) 	38
Income from Continuing Operations Before Taxes 	1,717 	(503) 	(128) 	258 	(37) 	(410) 	2,127
Income Tax Provision (Benefit) 	503 	(98) (4) (15) (4) 57 (4) (8) (4) (64) 	567
Net Income from Continuing Operations 	1,214 	(405) 	(113) 	201 	(29) 	(346) 	1,560
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 1,213 	(405) 	(113) 	201 	(29) 	(346) 	1,559
Earnings per Common Share Assuming Dilution from
Continuing Operations 0.48	$ 	(0.16) 	(0.04) 	0.08 	(0.01) 	(0.13) 	0.61	$
Tax Rate 	29.3% 	26.7%
June YTD
Cost of sales 	6,303	$ 	842 	65 	225 (3) 1,132 	5,171	$
Selling, general and administrative 	4,468 	35 	4 	39 	4,429
Research and development 	6,732 	34 	13 	47 	6,685
Restructuring costs 	380 	380 	380 	-
Other (income) expense, net 	(558) 	89 	(819) 	(730) 	172
Income from Continuing Operations Before Taxes 	4,704 	(1,000) 	(462) 	819 	(225) 	(868) 	5,572
Income Tax Provision (Benefit) 	741 	(187) (4) (56) (4) 180 (4) (257) (4) (320) 	1,061
Net Income from Continuing Operations 	3,963 	(813) 	(406) 	639 	32 	(548) 	4,511
Net Income from Continuing Operations Attributable
to Merck & Co., Inc. 3,958 	(813) 	(406) 	639 	32 	(548) 	4,506
Earnings per Common Share Assuming Dilution from
Continuing Operations 1.56	$ 	(0.32) 	(0.16) 	0.25 	0.02 	(0.21) 	1.77	$
Tax Rate 	15.8% 	19.0%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management
believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP
measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-
GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other
costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense,
net, for the second quarter and six month period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint
venture and a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. Amount included in other (income) expense, net, for the six month period was partially offset by royalty income
related to the prior termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents charges for the discontinuation of COVID-19 development programs.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the six month period also includes a
$207 million net tax benefit related to the settlement of certain federal income tax matters.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
SECOND QUARTER AND SIX MONTHS ENDED JUNE 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are
excluded from the financial information provided below.
GAAP Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
Table 2b
In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone
payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the
charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s
non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation.
4

-- 5 of 10 --

1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) $15,901 	$14,593 	$30,494 	$10,627 	$11,402 	$22,029 	$13,154 	$13,521 	$48,704 	28 	31 	38 	41
PHARMACEUTICAL 	14,107 	12,756 	26,863 	9,238 	9,980 	19,218 	11,496 	12,039 	42,754 	28 	33 	40 	45
Oncology
Keytruda 	4,809 	5,252 	10,061 	3,899 	4,176 	8,076 	4,534 	4,577 	17,186 	26 	30 	25 	29
Alliance Revenue – Lynparza (2) 266 	275 	541 	228 	248 	475 	246 	268 	989 	11 	17 	14 	18
Alliance Revenue – Lenvima (2) 227 	231 	459 	130 	181 	310 	188 	206 	704 	28 	33 	48 	51
Alliance Revenue – Reblozyl (3) 52 	33 	86 	17 	17 	* 	* 	* 	*
Vaccines (4)
Gardasil / Gardasil 9 	1,460 	1,674 	3,133 	917 	1,234 	2,151 	1,993 	1,528 	5,673 	36 	40 	46 	48
ProQuad / M-M-R II / Varivax 	470 	578 	1,047 	449 	516 	965 	661 	509 	2,135 	12 	14 	9 	10
RotaTeq 	216 	173 	389 	158 	208 	366 	227 	213 	807 	-17 	-14 	6 	8
Pneumovax 23 	173 	153 	325 	171 	152 	323 	277 	292 	893 	1 	4 	1 	3
Vaqta 	36 	35 	71 	34 	56 	90 	48 	41 	179 	-38 	-38 	-21 	-21
Hospital Acute Care
Bridion 	395 	426 	821 	340 	387 	727 	369 	436 	1,532 	10 	15 	13 	17
Prevymis 	94 	103 	197 	82 	93 	174 	96 	100 	370 	11 	18 	13 	19
Primaxin 	58 	64 	122 	65 	60 	125 	70 	65 	259 	6 	8 	-2 	-2
Dificid 	52 	66 	119 	27 	34 	61 	54 	60 	175 	95 	95 	95 	95
Noxafil 	57 	60 	118 	67 	66 	133 	64 	62 	259 	-8 	-3 	-11 	-7
Invanz 	52 	46 	99 	57 	48 	104 	53 	45 	202 	-3 	1 	-5 	-2
Cancidas 	53 	42 	95 	57 	54 	111 	56 	45 	212 	-23 	-20 	-15 	-13
Zerbaxa 	30 	46 	76 	(8) 	(1) 	(9) 	(2) 	10 	(1) 	* 	* 	* 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 72 	98 	170 	74 	74 	149 	100 	94 	342 	33 	33 	14 	15
Adempas (6) 61 	63 	124 	55 	74 	129 	59 	63 	252 	-14 	-5 	-4 	6
Virology
Lagevrio 	3,247 	1,177 	4,424 	952 	952 	* 	* 	* 	*
Isentress / Isentress HD 	158 	147 	305 	209 	192 	401 	189 	178 	769 	-24 	-19 	-24 	-20
Neuroscience
Belsomra 	69 	69 	137 	79 	78 	157 	81 	80 	318 	-12 	-2 	-13 	-5
Immunology
Simponi 	186 	181 	366 	214 	202 	416 	203 	206 	825 	-10 	1 	-12 	-3
Remicade 	61 	53 	114 	85 	75 	160 	73 	67 	299 	-29 	-19 	-29 	-20
Diabetes (7)
Januvia 	779 	756 	1,535 	809 	784 	1,593 	852 	878 	3,324 	-4 	1 	-4 	-
Janumet 	454 	476 	931 	486 	477 	962 	487 	514 	1,964 	0 	6 	-3 	2
Other Pharmaceutical (8) 520 	479 	998 	554 	512 	1,069 	518 	533 	2,118 	-6 	-3 	-7 	-3
ANIMAL HEALTH 	1,482 	1,467 	2,949 	1,418 	1,472 	2,890 	1,417 	1,261 	5,568 	- 	5 	2 	7
Livestock 	832 	826 	1,658 	819 	821 	1,640 	864 	791 	3,295 	1 	6 	1 	7
Companion Animals 	650 	641 	1,291 	599 	651 	1,250 	553 	470 	2,273 	-2 	3 	3 	7
Other Revenues (9) 312 	370 	682 	(29) 	(50) 	(79) 	241 	221 	382 	* 	* 	* 	*
* 200% or greater
2022 	2021 	2Q 	June YTD
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,305 million and $1,300 million in the first and second quarter of 2022, respectively, and $1,363 million, $1,330 million, $1,417 million and $1,475 million in the first,
second, third and fourth quarter of 2021, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues related to the receipt
of upfront and milestone payments for out-licensed products were $114 million and $32 million in the first and second quarter of 2022, respectively, and $56 million, $135 million and $27 million in
the first, third and fourth quarter of 2021, respectively.
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $2,481 million and $2,709 million in the first and second quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the first,
second, third and fourth quarter of 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
5

-- 6 of 10 --

2Q 2022 	2Q 2021 	% Change 	2Q 2022 	2Q 2021 	% Change 	2Q 2022 	2Q 2021 	% Change
TOTAL SALES (1) $14,593 	$11,402 	28 	$6,238 	$5,100 	22 	$8,355 	$6,301 	33
PHARMACEUTICAL 	12,756 	9,980 	28 	5,726 	4,647 	23 	7,030 	5,333 	32
Oncology
Keytruda 	5,252 	4,176 	26 	3,197 	2,347 	36 	2,055 	1,829 	12
Alliance Revenue - Lynparza (2) 275 	248 	11 	143 	124 	15 	132 	124 	7
Alliance Revenue - Lenvima (2) 231 	181 	28 	128 	88 	46 	103 	93 	11
Alliance Revenue - Reblozyl (3) 33 	* 	28 	* 	5 	*
Vaccines (4)
Gardasil / Gardasil 9 	1,674 	1,234 	36 	428 	454 	-6 	1,245 	781 	60
ProQuad / M-M-R II / Varivax 	578 	516 	12 	434 	386 	13 	143 	130 	10
RotaTeq 	173 	208 	-17 	98 	111 	-11 	75 	97 	-23
Pneumovax 23 	153 	152 	1 	94 	100 	-6 	59 	52 	14
Vaqta 	35 	56 	-38 	16 	22 	-27 	19 	34 	-45
Hospital Acute Care
Bridion 	426 	387 	10 	237 	197 	20 	190 	190 	-
Prevymis 	103 	93 	11 	47 	37 	28 	56 	56 	-
Dificid 	66 	34 	95 	63 	32 	100 	3 	2 	30
Primaxin 	64 	60 	6 	174 	64 	60 	6
Noxafil 	60 	66 	-8 	16 	14 	11 	45 	52 	-14
Zerbaxa 	46 	(1) 	* 	22 	(2) 	* 	24 	1 	*
Invanz 	46 	48 	-3 	2 	(4) 	-139 	45 	52 	-13
Cancidas 	42 	54 	-23 	2 	1 	* 	39 	53 	-26
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 98 	74 	33 	88 	81 	9 	10 	(7) 	*
Adempas (6) 63 	74 	-14 	63 	74 	-14
Virology
Lagevrio 	1,177 	* 	* 	1,177 	*
Isentress / Isentress HD 	147 	192 	-24 	67 	74 	-10 	80 	118 	-32
Neuroscience
Belsomra 	69 	78 	-12 	19 	14 	34 	50 	63 	-22
Immunology
Simponi 	181 	202 	-10 	181 	202 	-10
Remicade 	53 	75 	-29 	53 	75 	-29
Diabetes (7)
Januvia 	756 	784 	-4 	301 	284 	6 	455 	500 	-9
Janumet 	476 	477 	- 	105 	74 	43 	371 	403 	-8
Other Pharmaceutical (8) 479 	512 	-6 	191 	213 	-10 	288 	299 	-4
ANIMAL HEALTH 	1,467 	1,472 	- 	477 	459 	4 	990 	1,012 	-2
Livestock 	826 	821 	1 	164 	161 	2 	662 	659 	-
Companion Animals 	641 	651 	-2 	313 	298 	5 	328 	353 	-7
Other Revenues (9) 370 	(50) 	* 	35 	(6) 	* 	335 	(44) 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
Table 3a
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
SECOND QUARTER 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
(9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues related to the receipt of milestone payments
for out-licensed products were $32 million in the second quarter of 2022.
Global 	U.S. 	International
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,709 million in the second quarter of 2022 and $2,293 million in the second quarter of 2021.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,300 million in the second quarter of 2022 and $1,330 million in the second quarter of 2021.
(8) Includes Pharmaceutical products not individually shown above.
6

-- 7 of 10 --

June YTD
2022
June YTD
2021 	% Change
June YTD
2022
June YTD
2021 	% Change
June YTD
2022
June YTD
2021 	% Change
TOTAL SALES (1) $30,494 	$22,029 	38 	$13,577 	$9,890 	37 	$16,917 	$12,139 	39
PHARMACEUTICAL 	26,863 	19,218 	40 	12,498 	8,941 	40 	14,364 	10,277 	40
Oncology
Keytruda 	10,061 	8,076 	25 	5,976 	4,528 	32 	4,085 	3,548 	15
Alliance Revenue - Lynparza (2) 541 	475 	14 	283 	242 	17 	257 	233 	10
Alliance Revenue - Lenvima (2) 459 	310 	48 	284 	173 	64 	175 	137 	27
Alliance Revenue - Reblozyl (3) 86 	* 	55 	* 	30 	*
Vaccines (4)
Gardasil / Gardasil 9 	3,133 	2,151 	46 	846 	766 	10 	2,287 	1,385 	65
ProQuad / M-M-R II / Varivax 	1,047 	965 	9 	805 	718 	12 	243 	246 	-2
RotaTeq 	389 	366 	6 	273 	229 	19 	116 	137 	-16
Pneumovax 23 	325 	323 	1 	212 	173 	22 	114 	150 	-24
Vaqta 	71 	90 	-21 	45 	47 	-4 	25 	43 	-40
Hospital Acute Care
Bridion 	821 	727 	13 	432 	364 	19 	389 	363 	7
Prevymis 	197 	174 	13 	87 	72 	21 	110 	103 	7
Primaxin 	122 	125 	-2 	1 	* 	122 	125 	-2
Dificid 	119 	61 	95 	113 	56 	100 	6 	4 	38
Noxafil 	118 	133 	-11 	25 	29 	-13 	92 	104 	-11
Invanz 	99 	104 	-5 	2 	* 	96 	104 	-7
Cancidas 	95 	111 	-15 	4 	3 	15 	91 	108 	-16
Zerbaxa 	76 	(9) 	* 	40 	(4) 	* 	36 	(5) 	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 170 	149 	14 	159 	149 	7 	11 	*
Adempas (6) 124 	129 	-4 	124 	129 	-4
Virology
Lagevrio 	4,424 	* 	1,523 	* 	2,901 	*
Isentress / Isentress HD 	305 	401 	-24 	128 	145 	-12 	177 	256 	-31
Neuroscience
Belsomra 	137 	157 	-13 	39 	32 	22 	98 	125 	-22
Immunology
Simponi 	366 	416 	-12 	366 	416 	-12
Remicade 	114 	160 	-29 	114 	160 	-29
Diabetes (7)
Januvia 	1,535 	1,593 	-4 	626 	632 	-1 	909 	961 	-5
Janumet 	931 	962 	-3 	168 	158 	7 	762 	805 	-5
Other Pharmaceutical (8) 998 	1,069 	-7 	372 	429 	-13 	628 	640 	-2
ANIMAL HEALTH 	2,949 	2,890 	2 	951 	896 	6 	1,998 	1,994 	-
Livestock 	1,658 	1,640 	1 	335 	318 	6 	1,322 	1,322 	-
Companion Animals 	1,291 	1,250 	3 	616 	578 	7 	676 	672 	-
Other Revenues (9) 682 	(79) 	* 	128 	53 	142 	555 	(132) 	*
* 200% or greater
Sum of U.S. plus international may not equal global due to rounding.
Table 3b
Global 	U.S. 	International
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS
JUNE YEAR-TO-DATE 2022
(AMOUNTS IN MILLIONS)
(UNAUDITED)
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $146 million and $56 million on a global basis for June YTD 2022 and 2021, respectively.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment.
(4) Total Vaccines sales were $5,191 million and $4,102 million on a global basis for June YTD 2022 and 2021, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $2,605 million and $2,693 million on a global basis for June YTD 2022 and 2021, respectively.
(1) Only select products are shown.
7

-- 8 of 10 --

TOTAL PHARMACEUTICAL 	$14,107 	$12,756 	$26,863 	$9,238 	$9,980 	$19,218 	$11,496 	$12,039 	$42,754 	28 	40
United States 	6,773 	5,726 	12,499 	4,294 	4,647 	8,941 	5,670 	5,790 	20,401 	23 	40
% Pharmaceutical Sales 	48.0% 	44.9% 	46.5% 	46.5% 	46.6% 	46.5% 	49.3% 	48.1% 	47.7%
Europe (1) 3,309 	2,677 	5,986 	2,276 	2,404 	4,680 	2,445 	2,655 	9,780 	11 	28
% Pharmaceutical Sales 	23.5% 	21.0% 	22.3% 	24.6% 	24.1% 	24.4% 	21.3% 	22.1% 	22.9%
China 	1,113 	1,355 	2,468 	688 	944 	1,632 	1,278 	1,352 	4,262 	44 	51
% Pharmaceutical Sales 	7.9% 	10.6% 	9.2% 	7.4% 	9.5% 	8.5% 	11.1% 	11.2% 	10.0%
Japan 	965 	1,092 	2,057 	607 	637 	1,244 	614 	771 	2,629 	71 	65
% Pharmaceutical Sales 	6.8% 	8.6% 	7.7% 	6.6% 	6.4% 	6.5% 	5.3% 	6.4% 	6.1%
Asia Pacific (other than China and Japan) 	786 	854 	1,640 	437 	442 	879 	450 	488 	1,817 	93 	87
% Pharmaceutical Sales 	5.6% 	6.7% 	6.1% 	4.7% 	4.4% 	4.6% 	3.9% 	4.1% 	4.2%
Latin America 	435 	453 	888 	353 	379 	732 	434 	421 	1,587 	20 	21
% Pharmaceutical Sales 	3.1% 	3.6% 	3.3% 	3.8% 	3.8% 	3.8% 	3.8% 	3.5% 	3.7%
Eastern Europe/Middle East/Africa 	450 	339 	789 	357 	318 	675 	362 	278 	1,315 	7 	17
% Pharmaceutical Sales 	3.2% 	2.7% 	2.9% 	3.9% 	3.2% 	3.5% 	3.1% 	2.3% 	3.1%
Canada 	189 	166 	354 	160 	157 	318 	164 	167 	650 	5 	12
% Pharmaceutical Sales 	1.3% 	1.3% 	1.3% 	1.7% 	1.6% 	1.7% 	1.4% 	1.4% 	1.5%
Other 	87 	94 	182 	66 	52 	117 	79 	117 	313 	81 	56
% Pharmaceutical Sales 	0.6% 	0.6% 	0.7% 	0.8% 	0.4% 	0.5% 	0.8% 	0.9% 	0.8%
2022 	2021 	% Change
MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
June YTD
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
3Q 	4Q 	Full Year 	2Q
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
2Q22 	2Q21
June YTD
2022
June YTD
2021
Interest income 	(15)	$ 	(9)	$ 	(22)	$ 	(20)	$
Interest expense 	240 	202 	483 	401
Exchange losses 	86 	114 	124 	155
Loss (income) from investments in equity securities, net (1) 284 	(280) 	991 	(854)
Net periodic defined benefit plan (credit) cost other than service cost 	(27) 	(110) 	(148) 	(199)
Other, net 	(130) 	(20) 	(280) 	(41)
Total 	438	$ 	(103)	$ 	1,148	$ 	(558)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests
in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --